| Original language | English (US) |
|---|---|
| Pages (from-to) | 2371-2372 |
| Number of pages | 2 |
| Journal | Neuropsychopharmacology |
| Volume | 36 |
| Issue number | 12 |
| DOIs |
|
| State | Published - Nov 2011 |
Bibliographical note
Funding Information:This work was supported by NIH grants (5R01HD052074-05 and 5R01MH086000-01A2). Dr SH Fatemi has received patents for use of Reelin as a diagnostic marker for psychiatric disorders. He has not derived any financial gains from these patents. Dr SH Fatemi acknowledges the critical review of this commentary by T Folsom, R Kneeland, S Liesch, and Dr M Karkhane Yousefi.